NEUARTIGE THERAPIE

Patent europeic · EP3277813 · En vigur

Inscripziun en il register

Numer da publicaziun
EP3277813
Numer da la dumonda
EP16715897
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
24-03-2016
Publitgà
07-02-2018
Concedì
16-09-2020
La protecziun finescha il pli tard
23-03-2036
Proxima taxa annuala scadenta
31-03-2027
Classas IPC
C12N 15/113 (2010.01)
A61K 31/713 (2006.01)
Prioritad
GB 201505382 29.03.2015
Dumonda PCT
PCT/IB2016/051674 24.03.2016
Publicaziun PCT
WO2016/157044 06.10.2016
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 01-04-2026

    Midada

    Published in Swissreg on 01.04.2026

  2. 01-04-2025

    Midada

    Published in Swissreg on 01.04.2025

  3. 01-04-2024

    Midada

    Published in Swissreg on 01.04.2024

  4. 26-04-2023

    Midada

    Published in Swissreg on 26.04.2023

  5. 16-04-2021

    Transferì

    Owner
    Linnane Pharma AB, Slottsgatan 32, 21133 Malmo, Sweden → Selectimmune Pharma AB, Klinikgatan 32, 22242 Lund, Sweden

    Published in Swissreg on 16.04.2021

  6. 23-12-2020

    Represchentant inscrit

    Representative
    Latscha Schöllhorn Partner AG, Grellingerstrasse 60, 4052 Basel

    Published in Swissreg on 23.12.2020

  7. 16-09-2020

    Concedì

    Published in Swissreg on 16.09.2020

Partidas

Possessur

Selectimmune Pharma AB

Klinikgatan 32, 22242 Lund, SE

Represchentant

Latscha Schöllhorn Partner AG

Grellingerstrasse 60, 4052 Basel

Inventur

PUTHIA, Manoj

S-223 62 Lund, SE

SVANBORG, Catharina

21133 Malmo, SE

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.